文献速递角膜与眼表疾病

Lifitegrast治疗干眼病:一项III期随机双盲安慰剂对照试验(OPUS-3)结果

Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
PubMed 文献 · Ophthalmology · 2016-10-27

OPUS-3是一项为期12周的III期随机双盲多中心安慰剂对照研究,纳入711例干眼病患者,评估5.0% Lifitegrast滴眼液每日两次与安慰剂的疗效和安全性。结果显示Lifitegrast在第84天显著改善眼干评分(治疗效应7.16,95%CI 3.04-11.28,P=0.0007),第14天即观察到改善,且耐受性良好。

要点

  • Lifitegrast在第84天显著改善眼干评分,治疗效应7.16(95%CI 3.04-11.28,P=0.0007)。
  • 眼干评分改善最早在第14天出现,第42天治疗效应9.32(95%CI 5.44-13.20)。
  • 多数治疗中出现的不良事件为轻至中度,未报告严重眼部不良事件。

核心结论

  • Lifitegrast显著改善干眼病患者的眼干症状(以眼干评分衡量),最早在第14天观察到改善,且似乎耐受性良好。

研究设计与样本

  • 12周、III期、随机、双盲、多中心、安慰剂对照研究(OPUS-3,NCT02284516)。
  • 纳入年龄≥18岁、Schirmer泪液试验(无麻醉)≥1且≤10 mm、角膜荧光素染色评分≥2.0(0-4分)、眼干评分≥40(0-100视觉模拟量表)、入组前30天内有使用人工泪液史的成人干眼病患者。
  • 经过14天安慰剂导入期后,参与者按1:1随机分配至5.0% Lifitegrast滴眼液或安慰剂,每日两次,持续84天。
  • 共随机分配711例参与者:安慰剂组356例,Lifitegrast组355例(意向治疗人群)。

主要发现

  • 第84天,Lifitegrast组眼干评分较基线的改善显著大于安慰剂组(治疗效应7.16;95%CI 3.04-11.28;P=0.0007)。
  • 第42天眼干评分较基线变化显著有利于Lifitegrast(治疗效应9.32;95%CI 5.44-13.20;P<0.0001)。
  • 第14天眼干评分较基线变化显著有利于Lifitegrast(治疗效应7.85;95%CI 4.33-11.37;P<0.0001)。
  • 第84天、42天或14天,两组间眼部不适评分(ODS)未观察到统计学显著差异。
  • 第42天,Lifitegrast组在瘙痒(名义P=0.0318)、异物感(名义P=0.0418)和眼部不适(P=0.0048)方面较安慰剂组改善更明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lifitegrast is a lymphocyte function-associated antigen-1 antagonist developed to reduce inflammation in dry eye disease (DED). We report the results of OPUS-3 (NCT02284516), a phase III study evaluating the efficacy and safety of lifitegrast versus placebo in participants with DED. DESIGN: Twelve-week, phase III, randomized, double-masked, multicenter, placebo-controlled study. PARTICIPANTS: Adults aged ≥18 years with Schirmer tear test (without anesthesia) ≥1 and ≤10 mm, corneal fluorescein staining score ≥2.0 (0-4 scale), eye dryness score (EDS) ≥40 (0-100 visual analogue scale [VAS]), and history of artificial tear use within 30 days of study entry. METHODS: After a 14-day placebo run-in, participants were randomized 1:1 to lifitegrast ophthalmic solution 5.0% or placebo twice daily for 84 days. MAIN OUTCOME MEASURES: The primary efficacy end point was change from baseline to day 84 in EDS. Key secondary efficacy end points were change from baseline to days 42 and 14 in EDS. Other secondary efficacy end points included additional VAS items (burning/stinging, itching, foreign body sensation, eye discomfort, photophobia, pain), ocular discomfort score (ODS), and safety/tolerability of lifitegrast versus placebo. RESULTS: In the study, 711 participants were randomized: placebo, 356; lifitegrast, 355 (intention-to-treat [ITT] population). At day 84, lifitegrast-treated participants experienced significantly greater improvement from baseline in EDS versus those receiving placebo (treatment effect [TE], 7.16; 95% confidence interval [CI], 3.04-11.28; P = 0.0007). Mean changes from baseline in EDS also significantly favored lifitegrast on days 42 (TE, 9.32; 95% CI, 5.44-13.20; P < 0.0001) and 14 (TE, 7.85; 95% CI, 4.33-11.37; P < 0.0001). No statistically significant differences were observed in ODS between treatment groups at days 84, 42, or 14. A greater improvement was observed in lifitegrast-treated participants at day 42 in itching (nominal P = 0.0318), foreign body sensation (nominal P = 0.0418), and eye discomfort (P = 0.0048) versus participants receiving placebo. Most treatment-emergent adverse events were mild to moderate in severity; no serious ocular adverse events were reported. CONCLUSIONS: Lifitegrast significantly improved symptoms of eye dryness, as measured by EDS, versus placebo in participants with DED. Improvement in EDS was observed as early as day 14. Lifitegrast appeared well tolerated.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). Ophthalmology. 2016. PMID: 28079022. doi:10.1016/j.ophtha.2016.09.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。